Raven Quinn

456 total citations
7 papers, 301 citations indexed

About

Raven Quinn is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Raven Quinn has authored 7 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Pathology and Forensic Medicine and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Raven Quinn's work include Lung Cancer Treatments and Mutations (3 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Cancer Diagnosis and Treatment (3 papers). Raven Quinn is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Cancer Diagnosis and Treatment (3 papers). Raven Quinn collaborates with scholars based in United States. Raven Quinn's co-authors include John D. Hainsworth, F. Anthony Greco, Mark S. Rubin, David R. Spigel, Ralph V. Boccia, Dana S. Thompson, Dianna Shipley, Howard A. Burris, Janice F. Eakle and Eric T. Lubiner and has published in prestigious journals such as Journal of Clinical Oncology, Lung Cancer and Clinical Lymphoma Myeloma & Leukemia.

In The Last Decade

Raven Quinn

7 papers receiving 293 citations

Peers

Raven Quinn
Samhita Chakraborty United States
M. Roušarová Czechia
Amna Khurshid Pakistan
Rema Rao United States
Aditya Shreenivas United States
Julie Meilleroux France
Alyssa Luvison United States
Géraldine Martineau France
Brita B. Jensen Denmark
Maria Karina Greece
Samhita Chakraborty United States
Raven Quinn
Citations per year, relative to Raven Quinn Raven Quinn (= 1×) peers Samhita Chakraborty

Countries citing papers authored by Raven Quinn

Since Specialization
Citations

This map shows the geographic impact of Raven Quinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raven Quinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raven Quinn more than expected).

Fields of papers citing papers by Raven Quinn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raven Quinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raven Quinn. The network helps show where Raven Quinn may publish in the future.

Co-authorship network of co-authors of Raven Quinn

This figure shows the co-authorship network connecting the top 25 collaborators of Raven Quinn. A scholar is included among the top collaborators of Raven Quinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raven Quinn. Raven Quinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
2.
Hainsworth, John D., F. Anthony Greco, Eric Raefsky, et al.. (2014). Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 14(4). 277–283. 18 indexed citations
3.
Gian, Victor G., Mark S. Rubin, Dianna Shipley, et al.. (2012). Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).. Journal of Clinical Oncology. 30(15_suppl). 7587–7587. 2 indexed citations
4.
Spigel, David R., F. Anthony Greco, Mark S. Rubin, et al.. (2012). Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung Cancer. 77(2). 359–364. 32 indexed citations
5.
Waterhouse, David, John D. Hainsworth, Frank A. Greco, et al.. (2012). Adjuvant carboplatin, docetaxel, bevacizumab, and erlotinib versus chemotherapy alone in patients with resected non-small cell lung cancer: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).. Journal of Clinical Oncology. 30(15_suppl). 7035–7035. 2 indexed citations
6.
Hainsworth, John D., Mark S. Rubin, David R. Spigel, et al.. (2012). Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute. Journal of Clinical Oncology. 31(2). 217–223. 235 indexed citations
7.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samhita Chakraborty Breakdown of academic impact, for papers by M. Roušarová Breakdown of academic impact, for papers by Amna Khurshid Breakdown of academic impact, for papers by Rema Rao Breakdown of academic impact, for papers by Aditya Shreenivas Breakdown of academic impact, for papers by Julie Meilleroux Breakdown of academic impact, for papers by Alyssa Luvison Breakdown of academic impact, for papers by Géraldine Martineau Breakdown of academic impact, for papers by Brita B. Jensen Breakdown of academic impact, for papers by Maria Karina
Rankless by CCL
2026